Summary
The synergistic interaction of cefotaxime and desacetylcefotaxime against 187 clinically significant anaerobic organisms was investigated. Fusobacterium nucleatum, Actinomyces odontolyticus, propionibacteria, lactobacilli, peptostreptococci, Streptococcus intermedius and Veillonella were sensitive to cefotaxime. Both Eubacteriurn lentum and Streptococcus morbillorum were resistant. The susceptibility of the clostridia varied from 0.125 to >256 mg/L; only 20% of species demonstrated synergy between cefotaxime and desacetylcefotaxime. The minimum inhibitory concentration (MIC) of cefotaxime against members of the genus Bacteroides ranged from 0.0625 to >256 mg/L. The MIC50 of cefotaxime to Bacteroides fragilis and B. vulgatus was lowered from 6 and 4 mg/L, respectively, to 2 and 1 mg/L, respectively, when 4 mg/L desacetylcefotaxime was added to the medium. Full or partial synergy was demonstrated by 50.7% of the Bacteroides species tested. While cefotaxime and desacetylcefotaxime act synergistically against many members of the genus Bacteroides, the MIC of at least 10% of strains is not affected by this> combination.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aldridge KE, Sanders CV, Marier RL. In vitro synergy and potentiation between cefotaxime and desacetylcefotaxime against clinical isolates of Bacteroides. Diagnostic Microbiology and Infectious Diseases 2: 47S–53S, 1984
Berenbaum MC. A method for testing for synergy with any number of agents. Journal of Infectious Diseases 137: 122–130, 1978
Elion GB, Singer S, Hitchings GH. Antagonists of nucleic acid derivatives, VIII. Synergism in combinations of biochemically related antimetabolites. Journal of Biological Chemistry 208: 477–488,1954
Ings RMJ, Fillastre J-P, Godin M, Leroy A, Humbert G. The pharmacokinetics of cefotaxime and its metabolites in subjects with normal and impaired renal function. Reviews of Infectious Diseases 4: S379–S391, 1982
Jones RN, Gerlach EH. Antimicrobial activity of HR 810 against 419 strict anaerobic bacteria. Antimicrobial Agents and Chemotherapy 27: 413–415, 1985
Jones RN, Thornsberry C. Cefotaxime: a review of in vitro antimicrobial properties and spectrum of activity. Reviews of Infectious Diseases 4: S300–S315, 1982
Jones RN, Barry AL, Packer RR. The activity of cefotaxime and desacetylcefotaxime alone and in combination against anaerobes and staphylococci. Diagnostic Microbiology and Infectious Diseases 2: 375–465, 1984a
Jones SR, Levinson W, Kimbrough RC, Ditmer-Schutz D. The use of cefotaxime in a community hospital. Drug Intelligence and Clinical Pharmacy 18: 144–149, 1984b
National Committee for Clinical Laboratory Standards. Reference agar dilution procedure for antimicrobial susceptibility testing of anaerobic bacteria. Vol. 5, No. 2. Villanova, PA, 1985
Reeves DS, White LO, Holt HA, Bahari D, Bywater MJ, et al. Human metabolism of cefotaxime. Journal of Antimicrobial Chemotherapy 6 (Suppl. A): 93–101, 1980
Smith JA, Henry D, Ngui-Yen J, Castell A, Coderre S. Comparison of agar dilution, microdilution and disk elution methods for measuring the synergy of cefotaxime and its metabolite against anaerobes. Journal of Clinical Microbiology 23: 1104–1108, 1986
Steers D, Foltz EL, Graves BS, Riden J. An inocula replicating apparatus for routine testing of bacterial susceptibility to antibiotics. Antibiotics and Chemotherapy (Basel) 9: 307–311, 1959
Swenson JM, Thornsberry C. Preparing inoculum for susceptibility testing of anaerobes. Journal of Clinical Microbiology 19: 321–325, 1984
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Devlin, H.R., Boskovski, L. The Synergistic Effect of Cefotaxime and Desacetylcefotaxime against Clinical Isolates of Anaerobic Bacteria. Drugs 35 (Suppl 2), 45–50 (1988). https://doi.org/10.2165/00003495-198800352-00011
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-198800352-00011